Class of 2021
Scientific Areas of Expertise: Developmental Therapeutics; Precision Oncology; Sarcoma
For central contributions to the development of novel treatments and personalized cancer care regimens for sarcoma patients, which have led to FDA and worldwide regulatory approval of various targeted therapies, including imatinib, pazopanib, and sunitinib, medications that have significantly altered the standard of care for sarcoma patients and those affected by gastrointestinal stromal tumors.